These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21738024)

  • 1. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.
    Martinkova J; Trejbalova L; Sasikova M; Benetin J; Valkovic P
    Clin Neuropharmacol; 2011; 34(5):179-81. PubMed ID: 21738024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.
    Thondam SK; Alusi S; O'Driscoll K; Gilkes CE; Cuthbertson DJ; Daousi C
    Clin Neuropharmacol; 2013; 36(5):170-2. PubMed ID: 24045609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.
    Perez-Lloret S; Rey MV; Fabre N; Ory F; Spampinato U; Brefel-Courbon C; Montastruc JL; Rascol O
    Clin Neuropharmacol; 2012; 35(6):261-5. PubMed ID: 23123689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
    De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
    Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
    Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
    Bayard S; Cochen De Cock V; Dauvillers Y
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
    Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling.
    Kolla BP; Mansukhani MP; Barraza R; Bostwick JM
    Psychosomatics; 2010; 51(3):271-3. PubMed ID: 20484726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impulse control disorders in Parkinson's disease.
    Vilas D; Pont-Sunyer C; Tolosa E
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S80-4. PubMed ID: 22166463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P; Eunson G; Bath L; Mulvihill A
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
    Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
    Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E; Crabbé J; Donckier J
    Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
    Elenkova A; Shabani R; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
    Hamidianjahromi A; Tritos NA
    Rev Endocr Metab Disord; 2022 Oct; 23(5):1089-1099. PubMed ID: 36125673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Yarman S; Kurtulmus N; Bilge A
    Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.